Immutep announced a major setback after an independent monitoring recommended stopping its Phase III TACTI-004 clinical trial of the cancer immunotherapy treatment following an interim “futility analysis.”
Share price has collapsed over 90% to 0.03
#ASX #IMM
1earthmedia.com/immuteps-res...